MedTrace Logo

Atorvastatin Therapy in the Treatment of Dyslipidemia in Children With Steroid Sensitive Nephrotic Syndrome

NCT07497776 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-03-27

No results posted yet for this study

Summary

To evaluate the effectiveness and safety of Atorvastatin therapy in children with dyslipidemia in steroid sensitive nephrotic syndrome.

Conditions

  • Dyslipidaemia

Interventions

DRUG

Atorvastatin

Atorvastatin 10 mg nightly dose

Sponsors & Collaborators

  • National Institute of Kidney Disease and Urology (NIKDU)

    lead OTHER

Principal Investigators

  • Saieef Zaman, MD · National institute of kidney Disease & Urology

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-27
Primary Completion
2025-08-30
Completion
2025-10-31

Countries

  • Bangladesh

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07497776 on ClinicalTrials.gov